Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes
mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would …

Solid organ transplantation (SOT) is a life-saving procedure and an established treatment for
patients with end-stage organ failure. However, transplantation is also accompanied by …

Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial
effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular …

Background: In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–
Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor …

Background The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–
glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is …

Background: Atrial fibrillation (AF) and atrial flutter (AFL) are associated with both diabetes
mellitus and its related comorbidities, including hypertension, obesity, and heart failure (HF) …

Background: Sodium glucose transporter-2 inhibitors reduce the risk of major adverse
cardiovascular events (MACE) in patients with type 2 diabetes mellitus and a history of …

The American College of Cardiology (ACC) develops a wide range of policy documents to
provide members with guidance on clinical topics. Although Clinical Practice Guidelines …

Background Empagliflozin slowed the progression of CKD in patients with type 2 diabetes
and cardiovascular disease in the EMPA-REG OUTCOME Trial. In a prespecified statistical …

OBJECTIVE Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve albuminuria in
patients with high cardiorenal risk. We report albuminuria change in the Dapagliflozin Effect …